Core Viewpoint - Eli Lilly reported a revenue of $15.56 billion for Q2 2025, representing a year-over-year growth of 38% [2] - The company has raised its full-year revenue guidance to between $60 billion and $62 billion, up from the previous estimate of $58 billion to $61 billion [2] Summary by Category - **Financial Performance** - Q2 2025 revenue reached $15.56 billion, marking a 38% increase compared to the same quarter last year [2] - Full-year revenue forecast adjusted to $60 billion to $62 billion, an increase from the prior range of $58 billion to $61 billion [2]

INDIANAPOLIS, Aug. 7, 2025 /PRNewswire/ --Eli Lilly and Company (NYSE: LLY) today announced its financial results for the second quarter of 2025. "Lilly delivered another quarter of strong performance, achieving 38% year-over-year revenue growth driven by robust sales of Zepbound and Mounjaro and sustained momentum across our key medicines," said David A. Ricks, Lilly chair and CEO. "Our pipeline continued to advance, highlighted by positive study results in oncology and cardiometabolic health—including Mou ...

| In the first of the county of the | . | | | | | --- | --- | --- | --- | --- | | | [] 和用 Int SEE EX BK JIK 事K 4K 11) 36 59 100 150: 300 1000 2490 3401 5401 Tok 15:110K = | | | ■ 10 - 00 - 10 2 - VS FIO B | | のの日のののののでやったときになったったいと | | | | | | 盘相日前 4316.01万 -- 成绩自美 6.4万 -- 超用价 760.000 | ■但: 645.600 | | | 00 C = 16500 | | 200 000 | | | | 1.82% | | 754.74 | | | | 134% | | PLE PER | | | | 10.85% | | 149.063 | | | | 0.16% | | 145,415 | | | | -0.17% | | 141.760 | | | | 4675 | | 738,122 | | | | (111) | | FREE | | ...

Clinical Trial Results - Lilly's experimental pill resulted in patients shedding approximately 11% of their body weight [1] Market Expectations - The 11% weight loss result falls on the lower end of Wall Street's expectations [1]

Core Insights - Eli Lilly's investigational oral medication orforglipron has shown significant efficacy in weight loss and cardiovascular risk factor improvement in the Phase 3 ATTAIN-1 trial, with plans for regulatory submission by year-end [1][4][5] Efficacy Results - In the ATTAIN-1 trial, orforglipron demonstrated a mean weight reduction of 12.4% (27.3 lbs) at the highest dose (36 mg) compared to 0.9% (2.2 lbs) with placebo after 72 weeks [1][2] - Key secondary endpoints showed that 59.6% of participants on the highest dose lost at least 10% of their body weight, while 39.6% lost at least 15% [1][2] - The treatment also resulted in significant reductions in cardiovascular risk markers, including non-HDL cholesterol and systolic blood pressure [1][3] Safety Profile - The safety profile of orforglipron was consistent with existing GLP-1 receptor agonists, with gastrointestinal-related adverse events being the most common [3] - The most frequently reported adverse events included nausea (28.9% to 35.9%), constipation (21.7% to 29.8%), and diarrhea (21.0% to 23.1%) across different doses, compared to lower rates in the placebo group [3] Clinical Trial Details - The ATTAIN-1 trial involved 3,127 participants with obesity or overweight and at least one weight-related medical issue, randomized to receive either orforglipron or placebo [6][7] - The trial's primary objective was to demonstrate superior body weight reduction compared to placebo after 72 weeks [6] Future Plans - Eli Lilly plans to present detailed results from the ATTAIN-1 trial at the European Association for the Study of Diabetes Annual Meeting in 2025 and publish findings in a peer-reviewed journal [4] - Additional results from the ATTAIN Phase 3 clinical trial program and the ACHIEVE Phase 3 program for type 2 diabetes are expected later this year [4]

Group 1 - The U.S. President Trump announced a plan to impose approximately 100% tariffs on chips and semiconductors, while stating that no fees would be charged for products manufactured in the U.S. [1] - Trump indicated that the U.S. would initially impose "small tariffs" on imported drugs, with plans to increase the rate to 150% within a year and potentially to 250% thereafter, although the initial tariff rate was not disclosed [1] - The market reacted calmly to the news, with several companies reporting that tariffs are not expected to significantly impact their performance this year; Pfizer's stock rose over 5%, while stocks of companies like Eli Lilly and Johnson & Johnson saw slight declines [1] Group 2 - Analysts estimate that a 15% tariff on drugs imported from the EU could increase costs for the pharmaceutical industry by up to $19 billion annually [1] - Trump has previously sent letters to 17 pharmaceutical companies, including major players like Eli Lilly, Johnson & Johnson, and Pfizer, urging them to lower drug prices in the U.S. [1]

Company Performance - Eli Liy's market capitalization has increased by approximately 860% since the current CEO took office [1] - The stock price is up a little bit more than 1,000% [1] Drug Development & Market - Eli Liy is the world's most valuable pharmaceutical company and a leader in the GLP-1 drug market [1] - GLP-1 drugs have become increasingly popular [1] - Eli Liy says it has a pill, eliminating the need for needles [1] - Eli Lily's experimental pill appears to work as well as the injected drug [2]

Core Viewpoint - The competitive advantage of Novo Nordisk established by semaglutide has been significantly diminished due to the emergence of Eli Lilly's tirzepatide, leading to a major downward revision of its 2025 performance guidance and a substantial decline in its market value [1][10][12]. Group 1: Company Performance - Novo Nordisk lowered its 2025 sales growth forecast from 16%-24% to 8%-14%, and profit growth from 19%-27% to 10%-16% [13][14]. - Following the guidance revision, Novo Nordisk's stock price dropped over 30% within four trading days, resulting in a market capitalization loss exceeding $60 billion [1][12]. - The company's market value has decreased by nearly $400 billion over the past year [1]. Group 2: Market Dynamics - The era of unlimited growth for GLP-1 drugs is coming to an end, with the market entering a phase of intense competition [1][16]. - Eli Lilly's tirzepatide has gained significant traction, quickly becoming a preferred option due to its superior weight loss efficacy compared to semaglutide [18][19]. - In the last quarter of 2024, tirzepatide surpassed Wegovy in weekly prescriptions in the U.S., indicating a shift in market leadership [19][20]. Group 3: Strategic Missteps - Novo Nordisk's conservative strategy of limiting demand for its products, such as withholding low-dose starter packs, has backfired, leading to supply shortages and a loss of market share [14][15]. - The company has been slow to adapt its commercialization strategy, lagging behind Eli Lilly in direct-to-consumer initiatives [15][20]. - Novo Nordisk's diversified strategy across multiple markets has diluted its focus, resulting in slower growth in key markets like the U.S. [15][22]. Group 4: Future Outlook - Eli Lilly is actively exploring new drug candidates and expanding its production capabilities, positioning itself for continued growth in the GLP-1 market [20][22]. - Novo Nordisk's future product pipeline, including CagriSema and Amycretin, faces challenges in meeting market expectations and achieving competitive advantages [23][24]. - The competitive landscape is shifting, with Eli Lilly's aggressive strategies and innovative approaches threatening Novo Nordisk's market position [18][24].

Company Performance - Eli Lilly was approaching a $1 trillion company valuation [1] - The company is currently facing missed targets [1] Market Dynamics & Risks - The company is facing tariff threats [1] - Investor doubts are emerging regarding the company [1]

Core Insights - Eli Lilly is expected to report earnings of $5.59 per share and sales of $14.7 billion on August 7, 2025, reflecting an increase from the previous year's earnings of $3.92 per share and sales of $11.3 billion [3] - Historically, Eli Lilly's stock has shown a pattern of negative one-day returns following earnings announcements, with a 56% decrease rate over the past five years and a median decline of -3.1% [2][7] Financial Performance - Eli Lilly has a market capitalization of $685 billion, with $49 billion in revenue, $20 billion in operating profits, and a net income of $11 billion over the past twelve months [4] - The company has recorded 18 earnings data points in the last five years, with 8 positive and 10 negative one-day returns, resulting in a 44% occurrence of positive returns [7] Trading Strategies - Traders may consider pre-earnings positioning based on historical probabilities and analyze immediate and medium-term returns post-earnings to guide their strategies [6] - A correlation analysis between short-term and medium-term returns can help traders identify suitable trades, particularly if 1D and 5D returns show strong correlation [8] Peer Performance - The performance of peers can influence Eli Lilly's stock reaction post-earnings, with historical data indicating that peer stock returns may impact pricing ahead of the earnings announcement [9]